Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 218-760-9 | CAS number: 2226-96-2
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
![](https://poisoncentres.echa.europa.eu/o/diss-blank-theme/images/factsheets/A-REACH/factsheet/print_toxicological-information.png)
Endpoint summary
Administrative data
Description of key information
The subacute oral toxicity of 4-Hydroxy TEMPO was tested in a standard OECD 407 guideline study. Liver and spleen were identified as the target organs. The NOAEL was set to 40 mg/kg bw/day.
Key value for chemical safety assessment
Repeated dose toxicity: via oral route - systemic effects
Endpoint conclusion
- Endpoint conclusion:
- adverse effect observed
- Dose descriptor:
- NOAEL
- 40 mg/kg bw/day
- Study duration:
- subacute
- Species:
- rat
- Quality of whole database:
- Study according to guideline
Repeated dose toxicity: inhalation - systemic effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: inhalation - local effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: dermal - systemic effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: dermal - local effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Additional information
Oral:
In a repeated dose toxicity study according to GLP and OECD Guideline 407 (92-0574-FGT), the test item was administered orally by gavage to 6 SD-rats per dose group and gender at 0, 8, 40, 200 or 1000 mg/kg bw/day for 28 days. Additional recovery groups of the same size, comprising vehicle and high dose animals, were monitored for an additional 14 days. There were no fatalities; body weight food consumption, serum chemistry and urinalysis remained unaffected. Apart from salivation, which was mainly observed in all high dose animals, no abnormal clinical signs occurred. The most prominent effects in the high dose groups were a decreased red blood cell count, haemoglobin and haematocrit and an increase of reticulocytes. Low corpuscular haemoglobin concentrations and high counts of segmental neutrophils were found in high dose females only. The decrease of red blood cell counts and haemoglobin concentration persisted throughout the recovery phase. Absolute and relative spleen and liver weights were increased in high dose animals of both sexes at the end of the dosing period, spleen weight reduction persisted throughout the recovery phase. High dose animals showed a reversible blackening of spleen hue. Histopathology revealed congestion and hemosiderin accumulation in the spleen of all high dose animals and the females of the 200 mg/kg bw/d group. In addition swelling of hepatocytes was noted in all high dose animals. All histopathological effects were detectable until the end of the recovery phase. Based on these findings, the liver and spleen were identified as the target organs. The NOAEL was set to 40 mg/kg bw/day.
Inhalation:
In accordance with column 2 of REACH Annex IX, the test repeated dose toxicity after inhalation (required in section 8.6) does not need to be conducted as repeated dose toxicity studies for oral application are available or will be proposed. Inhalation exposure is regarded negligible as the substance has a very low vapour pressure. In addition the solid substance consists of flakes which are very unlikely to be inhaled due to their big particle size. Thus, no test on repeated dose inhalation toxicity has to be conducted.
Dermal:
In accordance with column 2 of REACH Annex IX, the test repeated dose toxicity after dermal application (required in section 8.6) does not need to be conducted as a repeat dose toxicity study for oral application is available. The substance is not irritating and not sensitizing to the skin. No dermal effects are expected for repeated dose application to the skin and a low dermal absorption is expected due to the physico-chemical properties of the substance. Thus, no test on repeated dose dermal toxicity has to be conducted.
Justification for selection of repeated dose toxicity via oral route - systemic effects endpoint:
Adequate assay to address endpoint.
Justification for selection of repeated dose toxicity inhalation - systemic effects endpoint:
In accordance with column 2 of REACH Annex IX, the test repeated dose toxicity after inhalation does not need to be conducted as repeated dose toxicity studies for oral application are available.
Justification for selection of repeated dose toxicity inhalation - local effects endpoint:
In accordance with column 2 of REACH Annex IX, the test repeated dose toxicity after inhalation does not need to be conducted as repeated dose toxicity studies for oral application are available.
Justification for selection of repeated dose toxicity dermal - systemic effects endpoint:
In accordance with column 2 of REACH Annex IX, the test repeated dose toxicity after dermal application does not need to be conducted as repeated dose toxicity studies for oral application are available.
Justification for selection of repeated dose toxicity dermal - local effects endpoint:
In accordance with column 2 of REACH Annex IX, the test repeated dose toxicity after dermal application does not need to be conducted as repeated dose toxicity studies for oral application are available.
Repeated dose toxicity: via oral route - systemic effects (target organ) cardiovascular / hematological: spleen; digestive: liver
Justification for classification or non-classification
Based on the results of the subacute oral toxicity study, the test substance was classified as STOT RE cat 2 with H373 (May cause damage to organs through prolonged or repeated exposure) according to EU Classification, Labelling and Packaging of Substances and Mixtures (CLP) Regulation (EC) No 1272/2008.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
![ECHA](/o/diss-blank-theme/images/factsheets/A-REACH/factsheet/echa_logo.png)